

# Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2019

<https://marketpublishers.com/r/G104DA86F92BEN.html>

Date: December 2019

Pages: 65

Price: US\$ 2,625.00 (Single User License)

ID: G104DA86F92BEN

## Abstracts

Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2019

### SUMMARY

Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.

Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 4, 5, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Toxicology, Immunology, Musculoskeletal Disorders and Other Diseases which include indications Short Bowel Syndrome, Chemotherapy Effects, Chemotherapy-Induced Diarrhea (CID), Crohn's Disease (Regional Enteritis), Gastrointestinal Mucositis, Inflammation, Multiple Organ Failure (Multiple Organ Dysfunction Syndrome) and Osteoporosis.

The latest report Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key

players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)

The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects

The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Glucagon Like Peptide 2 Receptor (GLP2R) - Overview

Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development

Adocia SAS

Bainan Biotech ApS

Hanmi Pharmaceuticals Co Ltd

Huons Global Co Ltd

Naia Rare Diseases Inc

OPKO Health Inc

Pfizer Inc

PhaseBio Pharmaceuticals Inc

Sosei Heptares

Takeda Pharmaceutical Co Ltd

Zealand Pharma AS

Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles

apraglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elsiglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glepaglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HL-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-15912 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOD-1501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Agonize GLP2R for Intestinal Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-681 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teduglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teduglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teduglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZP-7570 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Products

Glucagon Like Peptide 2 Receptor (GLP2R) - Product Development Milestones

Featured News & Press Releases

Jun 26, 2019: Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome

May 17, 2019: Therachon to present data from ongoing Phase II Study of Apraglutide for Short Bowel Syndrome at Digestive Disease Week

May 17, 2019: U.S. FDA approves GATTEX (teduglutide) for children 1 year of age and older with Short Bowel Syndrome

May 07, 2019: Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome

May 03, 2019: Hanmi's short bowel syndrome treatment becomes orphan drug in US

Mar 25, 2019: Therachon presents data from preclinical and phase I clinical studies of Apraglutide for the treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference

Feb 05, 2019: Pharm-Olam enrolls patients in Zealand Pharma orphan drug study

Jan 16, 2019: Therachon is granted Orphan Drug Designation by US FDA for Apraglutide for the treatment of Short Bowel Syndrome

Nov 29, 2018: Therachon is granted Orphan Drug Designation in the European Union for apraglutide for the treatment of short bowel syndrome

Nov 13, 2018: U.S. FDA accepts for filing Shire's supplemental New Drug Application for GATTEX (teduglutide [rDNA origin]) for children with Short Bowel Syndrome

Oct 05, 2018: Zealand Pharma enrolls first patient in Phase III study of glepaglutide

May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.

Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome

Apr 09, 2018: Revestive is accepted for restricted use within NHS Scotland

Jan 23, 2018: New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Adocia SAS, H2 2019

Pipeline by Bainan Biotech ApS, H2 2019

Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2019

Pipeline by Huons Global Co Ltd, H2 2019

Pipeline by Naia Rare Diseases Inc, H2 2019

Pipeline by OPKO Health Inc, H2 2019

Pipeline by Pfizer Inc, H2 2019

Pipeline by PhaseBio Pharmaceuticals Inc, H2 2019

Pipeline by Sosei Heptares, H2 2019

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Pipeline by Zealand Pharma AS, H2 2019

Dormant Projects, H2 2019



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Adocia SAS

Bainan Biotech ApS

Hanmi Pharmaceuticals Co Ltd

Huons Global Co Ltd

Naia Rare Diseases Inc

OPKO Health Inc

Pfizer Inc

PhaseBio Pharmaceuticals Inc

Sosei Heptares

Takeda Pharmaceutical Co Ltd

Zealand Pharma AS

## I would like to order

Product name: Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/G104DA86F92BEN.html>

Price: US\$ 2,625.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G104DA86F92BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970